CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.

CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics is a biopharmaceutical company with operations in China and the U.S. focused on developing innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

CARsgen Therapeutics

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Media contact: pr@carsgen.com

JIC Genesis Fountain Healthcare Ventures

Kaitai Capital

Summer Capital

Lilly Asia Ventures

Loyal Valley Capital

Shiyu Capital

South China Venture Capital

Photon Fund

Jolly Innovation Ventures

KTB Ventures

"In the past six months, we have made significant progresses in technological innovation, product development, and business operations. Zevor-cel was successfully launched in China and has been included in nearly 20 provincial and municipal healthcare plans. The pivotal Phase II trial of satri-cel in China has completed patient enrollment. We are also actively exploring the potential of satri-cel in adjuvant therapy, aiming for greater clinical benefit for patients. Additionally, we are rapidly advancing CT071, which is manufactured with our CARcelerate® platform, while continuing to develop multiple allogeneic CAR T-cell products based on the THANK-uCAR® platform." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gmubHD2Y

#cartcelltherapy #biotech #hematology #oncology

"We are very pleased to announce the successful completion of patient enrollment in the pivotal Phase II clinical trial of satri-cel in China. This significant milestone marks another solid step forward in our development of CAR T-cell therapies for solid tumors. We extend our gratitude to all the investigators, the patients and their families for their trust and support. We look forward to the submission of New Drug Application and the approval in China, to benefit patients with gastric cancer. As one of the leading companies in the field of CAR T-cell therapies, we remain committed to addressing the major challenges faced by existing CAR T-cell therapies and will develop more innovative CAR-T products for cancer patients." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gZjZdQZa

The updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). 

https://lnkd.in/gEKkNrwb

#cartcelltherapy #eha2024 #multiplemyeloma #bcma #gprc5d #carcelerate

The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)"

https://lnkd.in/g3R_eYun

#eha #eha2024 #rrmm #cartcelltherapy #gprc5d

The final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting.

https://lnkd.in/gnsCAqeq

The FDA has granted IND clearance for CT071, an autologous CAR T-cell therapy candidate targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (MM) or relapsed/refractory primary plasma cell leukemia (PCL).

CT071 is manufactured with CARsgen's proprietary CARcelerate™ platform, which shortens the manufacturing time to less than 2 days and therefore yields younger, healthier, and possibly more potent CAR T cells compared to conventional manufacturing. 

https://lnkd.in/gjx2kUiH

#cartcelltherapy #GPRC5D #CARcelerate

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-265.13M -	-1.06B 301.33%	-4.74B 345.17%	-890.95M 81.19%	-747.39M 16.11%
depreciation and amortization	19.57M -	40.11M 104.96%	52.45M 30.76%	81.53M 55.46%	87.39M 7.19%
deferred income tax	39.70M -	703.43M 1,671.68%	4.15B 490.22%		51.43M -
stock based compensation	1.93M -	1.71M 11.05%	13.50M 687.86%	43.99M 225.79%	14.46M 67.14%
change in working capital	27.28M -	13.45M 50.70%	13.38M 0.54%	43.48M 225.00%	211.38M 386.12%
accounts receivables	-2.33K -	364 115.63%	-6.54K 1,897.53%	-2.61K 60.13%
inventory					-683K -
accounts payables
other working capital	27.29M -	13.45M 50.71%	13.39M 0.48%	43.48M 224.86%	212.06M 387.66%
other non cash items	-2.35M -	10.20M 533.04%	-6.64M 165.16%	78.89M 1,287.27%	-72.20M 191.52%
net cash provided by operating activities	-179.00M -	-295.15M 64.88%	-512.32M 73.58%	-643.05M 25.52%	-454.94M 29.25%
investments in property plant and equipment	-103.46M -	-18.73M 81.89%	-178.45M 852.51%	-138.61M 22.32%	-9.55M 93.11%
acquisitions net			2.32B -		47.15M -
purchases of investments			-4.76B -	-3.48B 26.82%	-2.04B 41.48%
sales maturities of investments	170.14M -		2.44B -	5.93B 142.54%	2.04B 65.61%
other investing activites	16.30M -	11.84M 27.38%	-2.29B 19,468.71%	82.60M 103.60%	1.65M 98.00%
net cash used for investing activites	82.98M -	-6.90M 108.31%	-2.47B 35,731.83%	2.39B 196.59%	39.25M 98.36%
debt repayment	-244.12M -	-157.78M 35.37%	-146.87M 6.92%	-327.75M 123.16%	-4.85M 98.52%
common stock issued			2.58B -	10.51M 99.59%	6.61M 37.08%
common stock repurchased
dividends paid
other financing activites	271.65M -	1.46B 437.55%	244.81M 83.23%	80.73M 67.02%	-303K 100.38%
net cash used provided by financing activities	27.53M -	1.30B 4,631.62%	2.67B 105.30%	-236.51M 108.84%	-22.14M 90.64%
effect of forex changes on cash	1.42M -	-53.93M 3,911.52%	-42.07M 21.99%	69.32M 264.77%	19.54M 71.81%
net change in cash	-67.08M -	946.49M 1,511.05%	-351.69M 137.16%	1.58B 548.34%	-418.28M 126.53%
cash at beginning of period	163.55M -	96.48M 41.01%	1.04B 981.07%	691.28M 33.72%	2.27B 228.09%
cash at end of period	96.48M -	1.04B 981.07%	691.28M 33.72%	2.27B 228.09%	1.85B 18.44%
operating cash flow	-179.00M -	-295.15M 64.88%	-512.32M 73.58%	-643.05M 25.52%	-454.94M 29.25%
capital expenditure	-103.46M -	-18.73M 81.89%	-178.45M 852.51%	-138.61M 22.32%	-9.55M 93.11%
free cash flow	-282.46M -	-313.88M 11.12%	-690.77M 120.07%	-781.66M 13.16%	-464.48M 40.58%

2171

COM:CARSGEN

CARsgen Therapeutics

Last Close

7.02

25/11 08:08

Market Cap

2.36B

Beta: -

Volume Today

8.53M

Avg: -

Preview